Thursday, 27 June 2013

Study Finds Investigational Compound Empagliflozin Reduced Blood Glucose In Adults With Type 2 Diabetes And Impaired Kidney Function

Data presented at American Diabetes Association 73rd Scientific Sessions� also showed reductions in weight and blood pressure Boehringer Ingelheim and Eli Lilly and Company have announced results of a 52week Phase III clinical trial of the investigational compound empagliflozin*, which showed statistically significant reductions in HbA1c (average blood glucose) at week 24, with the addition of empagliflozin to existing oral glucoselowering therapy in people with Type 2 Diabetes (T2D) and mild to moderate renal impairment as measured by the estimated glomerular filtra... (Source: Health News from Medical News Today)

Source: http://www.medworm.com/index.php?rid=7373144&cid=u_0_26_f&fid=23292&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Fmnt%2Fhealthnews%2F%7E3%2F_70JO9lzayU%2F262454.php

phlebotomy training boston phlebotomy training mn phlebotomist courses

No comments:

Post a Comment